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Introduction
Assessment of both ischemic and bleeding risk is cru-
cial for the management of patients with coronary artery 
disease, especially patients with acute coronary syndromes 
(ACS) [1, 2]. At present, the use of the Global Registry for 
Acute Coronary Events (GRACE) risk score is recommended 
in patients presenting with non-ST-segment elevation ACS 
as it provides the most accurate stratification of risk both 
on admission and at discharge. However, there is growing 
interest in a more simplified approach to risk stratification 
[1, 3, 4]. Ranucci et al. introduced the Age, Creatinine and 
Ejection Fraction (ACEF) score, a simple, three-variable mod-
el for predicting mortality in patients undergoing elective 
cardiac surgery [5]. More importantly, the predictive value 
of the ACEF score was confirmed in different subsets of 
patients undergoing percutaneous coronary interventions 
(PCI) and transcatheter aortic valve implantation (TAVI) 
[6–10]. The ACEF score was associated with satisfactory 
predictive value not only in terms of short- and long-term 
mortality but also in terms of major adverse cardiovascular 
events, myocardial infarction, target lesion revasculariza-
tion, stent thrombosis and acute kidney injury after PCI [7, 
8, 10, 11]. However, the ability of the ACEF score to predict 
other in-hospital outcomes, including bleeding events in 
patients with ACS, is less established. 
Aim
Thus, we aimed to assess the value of the ACEF score 
in prediction of death as well as other in-hospital out-
comes in patients presenting with ACS in hospitals with-
out on-site invasive facilities.
Material and methods
The Krakow Registry of Acute Coronary Syndromes 
was a prospective, multicenter, observational registry de-
signed to examine in-hospital management and outcome 
of patients with ACS admitted to 29 community hospitals 
without on-site invasive facilities in this region of Poland 
[12–14]. Data were collected during two separate enroll-
ment periods: from February 2005 to March 2005 and from 
December 2005 to January 2006, and to minimize selection 
bias all consecutive patients with a  suspected diagnosis 
of ACS were included regardless of the treatment strategy 
or outcome. Data concerning baseline demographic and 
clinical characteristics, relevant laboratory results, pharma-
cotherapy during hospital stay and adverse cardiovascular 
outcomes were recorded on a  standardized, electronic, 
web-page based case report form. Standardized definitions 
were used for adverse events and final diagnosis [12–14]. 
The decision on transfer of patients for invasive diagnostics 
and treatment was left to the physician’s discretion.
The ACEF score was calculated using the following 
formula: age (years)/left ventricular ejection fraction (%) 
+ 1 (if baseline serum creatinine was > 2 mg/dl). Direct 
calculation of the ACEF score was not possible in 418 
(29.6%) patients due to at least one missing variable. 
In those patients missing data on the ACEF score were 
imputed using multiple imputation. Then, patients were 
divided into tertiles of the ACEF score.
Statistical analysis
Results are presented as numbers of patients (per-
centages) or medians (inter-quartile range) as applicable. 
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Differences in categorical variables were analyzed using 
the c2 test or Fisher’s exact test, as appropriate. Contin-
uous variables were compared using the Mann-Whitney 
U test and Kruskal-Wallis test, as appropriate. Predictors 
of in-hospital death were identified using multivariate 
Cox regression analysis. Forward selection in Cox regres-
sion with the p value for covariates to enter the model 
were set at the 0.05 level. All variables listed in Table I 
Table I. Baseline clinical characteristics
Variable Tertiles of ACEF score P-value
1st (n = 471) 2nd (n = 472) 3rd (n = 471)
Age [years] 56 (50–64) 71 (65–76) 76 (70–81) < 0.001
≥ 75 14 (3.0%) 124 (26.3%) 245 (52.0%) < 0.001
Male 266 (56.5%) 252 (53.4%) 266 (56.5%) 0.55
Body mass index [kg/m2] 26.8 (24.5–30.1) 26.4 (24.2–29.4) 26.6 (24.2–29.3) 0.15
Diabetes mellitus 61 (13.0%) 97 (20.6%) 134 (28.5%) < 0.001
Insulin 24 (5.1%) 46 (9.7%) 74 (15.7%) < 0.001
Arterial hypertension 339 (72.0%) 378 (80.1%) 370 (78.6%) 0.007
Hyperlipidemia 285 (60.5%) 269 (57.0%) 218 (46.3%) < 0.001
Previous angina 256 (54.4%) 335 (71.0%) 368 (78.1%) < 0.001
Previous myocardial infarction 80 (17.0%) 142 (30.1%) 225 (47.8%) < 0.001
Previous heart failure symptoms 18 (3.8%) 58 (12.3%) 191 (40.6%) < 0.001
Previous percutaneous coronary intervention 36 (7.6%) 51 (10.8%) 40 (8.5%) 0.21
Previous coronary artery bypass graft 8 (1.7%) 21 (4.4%) 30 (6.4%) 0.002
Previous stroke/transient ischemic attack 13 (2.8%) 27 (5.7%) 36 (7.6%) 0.004
Current smoker 178 (37.8%) 123 (26.1%) 107 (22.7%) < 0.001
Family history of coronary artery disease 85 (18.0%) 52 (11.0%) 64 (13.6%) 0.008
Peripheral arterial disease 19 (4.0%) 41 (8.7%) 81 (17.2%) < 0.001
Chronic kidney disease 2 (0.4%) 3 (0.6%) 63 (13.4%) < 0.001
Chronic obstructive pulmonary disease 20 (4.2%) 28 (5.9%) 87 (18.5%) < 0.001
Chest pain on admission 299 (63.5%) 299 (63.3%) 308 (65.4%) 0.77
Time from chest pain onset to admission [h] 7 (3–19) 8 (3–20) 7 (3–20) 0.55
Heart rate on admission [beats/min] 75 (66–86) 80 (70–95) 80 (75–100) < 0.001
Systolic blood pressure on admission [mm Hg] 140 (130–160) 150 (130–160) 140 (120–160) 0.003
Diastolic blood pressure on admission [mm Hg] 90 (80–100) 90 (80–100) 80 (80–100) 0.07
Cardiogenic shock on admission 8 (1.7%) 15 (3.2%) 36 (7.6%) < 0.001
Serum creatinine level [µmol/l] 81 (70–91) 87 (70–101) 99 (80–129) < 0.001
Left ventricular ejection fraction (%) 62 (60–68) 55 (50–60) 40 (30–48) < 0.001
Discharge diagnosis:
ST-segment elevation MI 97 (20.6%) 102 (21.6%) 135 (28.7%) < 0.001
Non-ST-segment elevation MI 87 (18.5%) 114 (24.2%) 179 (38.0%)
Unstable angina 236 (50.1%) 222 (47.0%) 141 (29.9%)
Stable angina 26 (5.5%) 22 (4.7%) 13 (2.8%)
Other 25 (5.3%) 12 (2.5%) 3 (0.6%)
Values are presented as number of patients (percentage) or median (interquartile range). MI – myocardial infarction.
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were tested, except for age, left ventricular ejection 
fraction, and baseline serum creatinine, which were in-
cluded as the ACEF score. Risk of in-hospital death was 
expressed as hazard ratios (HR) with 95% confidence in-
tervals (95% CI). Receiver-operating characteristic (ROC) 
curve analysis was used to assess the ability of the ACEF 
score to predict death as well as other in-hospital events. 
All tests were 2-tailed, and a p-value < 0.05 was consid-
ered statistically significant. All statistical analyses were 
performed using SPSS software, version 15.0 (SPSS Inc., 
Chicago, Illinois).
Results
In the studied group of 1,414 patients with initial 
diagnosis of ACS the median ACEF score was 1.315 
(1.049–1.700). A total of 471 patients had an ACEF score 
< 1.123 (the lowest tertile), 472 in the range 1.123–1.503 
(the mid tertile), and 471 ≥ 1.504 (the highest tertile). As 
expected, a higher ACEF score was linked per definition 
with older age and more frequent chronic kidney disease. 
In addition, a higher ACEF score was also associated with 
progressively increasing clinical comorbidity; namely, 
diabetes mellitus, previous angina, previous myocardial 
infarction, previous coronary artery bypass graft, periph-
eral arterial disease, chronic obstructive pulmonary dis-
ease, and cardiogenic shock on admission (Table I).
A total of 312 (22.1%) patients were transferred for 
invasive treatment during index hospital stay. The fre-
quency of transfer for invasive treatment was the low-
est in patients from the highest tertile of the ACEF score 
(24.6% in the lowest tertile, 25.2% in the mid tertile, and 
16.3% in the highest tertile; p = 0.001). In the group of 
1,102 patients remaining in the community hospitals for 
conservative treatment the median ACEF score was 1.321 
(1.060–1.761) and was higher than for transferred pa-
tients: 1.282 (1.024–1.512); p = 0.004. Total in-hospital 
mortality for conservatively treated patients was 7.9%. 
The risk of death was higher in patients with cardiogenic 
shock vs. non-shock (64.4% vs. 5.5%; p < 0.001), as well as 
in ST-elevation myocardial infarction (STEMI) vs. non-ST- 
elevation myocardial infarction (NSTEMI) vs. unstable an-
gina patients (22.7% vs. 12.1% vs. 1.5%; p < 0.001). More 
importantly, in-hospital mortality rates were higher in pa-
tients with a higher ACEF score (0.6% in the lowest tertile, 
3.7% in the mid tertile, and 18.3% in the highest ter-
tile; p < 0.001). The median ACEF score was lower in 
survivors than in non-survivors – 1.275 (1.035–1.658) 
vs. 2.089 (1.698–2.485); p < 0.001. In multivariate Cox 
regression analysis, independent predictors of in-hospi-
tal death for patients treated conservatively were: ACEF 
score (HR = 1.53, 95% CI: 1.27–1.85; p < 0.001), cardio-
genic shock (HR = 6.99, 95% CI: 4.22–11.57; p < 0.001), 
chronic obstructive pulmonary disease (HR = 1.90, 
Table II. Area under the curve (95% confidence 
interval) from receiver-operating characteristic 
curves of the age, creatinine, and ejection fraction 
(ACEF) score for in-hospital events in non-trans-
ferred patients
Parameter AUC (95% CI) P-value
Ischemic stroke 0.71 (0.55–0.86) 0.06
Major bleeding requiring blood 
transfusion
0.72 (0.58–0.87) 0.003
Ventricular tachycardia/ 
ventricular fibrillation
0.70 (0.60–0.81) 0.013
Atrial fibrillation 0.67 (0.59–0.76) 0.004
2nd to 3rd atrioventricular block 0.84 (0.78–0.90) 0.031
Pulmonary edema 0.81 (0.74–0.87) < 0.001
Death 0.83 (0.79–0.86) < 0.001
Figure 1. In-hospital complications and mortality stratified by the age, creatinine, and ejection fraction (ACEF) 
score tertiles in non-transferred patients
AV – atrioventricular, VT/VF – ventricular tachycardia/ventricular fibrillation.
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95% CI: 1.16–3.13; p = 0.011), and STEMI (HR = 2.39, 
95% CI: 1.52–3.76; p < 0.001). The ACEF score demon-
strated good accuracy as a predictor of in-hospital death, 
as expressed by a high area under the curve (AUC = 0.83, 
95% CI: 0.79–0.86; p < 0.001) – Table II and Figure 1. The 
predictive value was lower in the subgroup of patients 
with unstable angina (AUC = 0.70, 95% CI: 0.55–0.85; 
p = 0.06), but still satisfactory for patients with STEMI 
(AUC = 0.76, 95% CI: 0.69–0.83; p < 0.001) and NSTEMI 
(AUC = 0.81, 95% CI: 0.75–0.87; p < 0.001). As shown in 
Figure 1, the ACEF score was associated with increased 
risk of rhythm and conduction disturbances, as well as 
pulmonary edema and bleeding events requiring blood 
transfusion during the index hospital stay. In contrast, 
there was no difference in the frequency of ischemic 
stroke between study groups. The ACEF score demon-
strated good accuracy as a predictor of in-hospital death 
as well as other outcomes (Table II).
Discussion
Our study has confirmed the ability of the ACEF score 
to predict not only in-hospital mortality but also other 
clinical events including bleeding. These findings were 
somewhat expected, as two of three components of the 
ACEF score, i.e. age and serum creatinine level, are strong 
predictors of ischemic and bleeding events in the setting 
of ACS [1, 2, 15, 16]. However, the performance of the 
ACEF score itself in the context of non-ischemic events in 
ACS, especially in patients treated conservatively during 
the index hospital stay, has not been previously tested. 
The observed AUC of 0.72 for bleeding requiring blood 
transfusion seems to be comparable to the values re-
ported for other bleeding risk scores [15], but it should 
be confirmed in other cohorts. The ACEF score may have 
a limited value for the selection of patients with the high-
est benefit of an invasive strategy in patients with non-
ST-segment ACS, as symptoms of the ongoing ischemia 
and/or haemodynamic instability may be more import-
ant for the decision-making process.
Several important limitations of the present study 
should be acknowledged. First of all, data concerning 
mortality in the group of patients transferred for invasive 
treatment during the index hospital stay, as well as long-
term clinical follow-up data for all patients, were not avail-
able. Secondly, taking into account the enrollment period, 
the study findings may not correspond to the current 
clinical practice with broad access to invasive treatment 
and new antiplatelet and antithrombotic drugs. Thus, the 
study findings should be considered primarily as explor-
atory and hypothesis-generating. On the other hand, the 
findings may have some relevance for countries/regions 
with limited access to invasive management of ACS. Third-
ly, direct calculation of the ACEF score was not possible in 
one third of patients. However, the results were similar 
in analyses conducted without multiple imputation (data 
not shown). Also, the performance of the ACEF score was 
not compared to other risk scores. Despite these limita-
tions, the observed relationship between ACEF score and 
in-hospital complications and mortality of a selected co-
hort of conservatively treated patients with ACS is clini-
cally important and unlikely to be influenced by the study 
limitations. However, these findings should be confirmed 
in a larger population of patients with ACS.
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